In addition, a recombinant human IL-1R antagonist plus one of the standard chemotherapy regimens, gemcitabine, significantly reduced tumor burden when compared to the gemcitabine treatment alone in a pancreatic ductal adenocarcinoma orthotopic xenograft mouse model88. This evidence concerns the gene IL1R1 and neoplasm.